{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T23:13:37Z","timestamp":1794611617718,"version":"4.9.1"},"reference-count":75,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,12,18]],"date-time":"2019-12-18T00:00:00Z","timestamp":1576627200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2019,12,18]],"date-time":"2019-12-18T00:00:00Z","timestamp":1576627200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Neuroinflammation is often associated with blood-brain-barrier dysfunction, which contributes to neurological tissue damage. Here, we reveal the pathophysiology of Susac syndrome (SuS), an enigmatic neuroinflammatory disease with central nervous system (CNS) endotheliopathy. By investigating immune cells from the blood, cerebrospinal fluid, and CNS of SuS patients, we demonstrate oligoclonal expansion of terminally differentiated activated cytotoxic CD8\n                    <jats:sup>+<\/jats:sup>\n                    T cells (CTLs). Neuropathological data derived from both SuS patients and a newly-developed transgenic mouse model recapitulating the disease indicate that CTLs adhere to CNS microvessels in distinct areas and polarize granzyme B, which most likely results in the observed endothelial cell injury and microhemorrhages. Blocking T-cell adhesion by anti-\u03b14 integrin-intervention ameliorates the disease in the preclinical model. Similarly, disease severity decreases in four SuS patients treated with natalizumab along with other therapy. Our study identifies CD8\n                    <jats:sup>+<\/jats:sup>\n                    T-cell-mediated endotheliopathy as a key disease mechanism in SuS and highlights therapeutic opportunities.\n                  <\/jats:p>","DOI":"10.1038\/s41467-019-13593-5","type":"journal-article","created":{"date-parts":[[2019,12,18]],"date-time":"2019-12-18T06:02:55Z","timestamp":1576648975000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":138,"title":["CD8+ T cell-mediated endotheliopathy is a targetable mechanism of neuro-inflammation in Susac syndrome"],"prefix":"10.1038","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4872-9189","authenticated-orcid":false,"given":"Catharina C.","family":"Gross","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e9line","family":"Meyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4923-4492","authenticated-orcid":false,"given":"Urvashi","family":"Bhatia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lidia","family":"Yshii","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3207-9684","authenticated-orcid":false,"given":"Ilka","family":"Kleffner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5802-8047","authenticated-orcid":false,"given":"Jan","family":"Bauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3003-4677","authenticated-orcid":false,"given":"Anna R.","family":"Tr\u00f6scher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3855-4706","authenticated-orcid":false,"given":"Andreas","family":"Schulte-Mecklenbeck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8976-7811","authenticated-orcid":false,"given":"Sebastian","family":"Herich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3717-5176","authenticated-orcid":false,"given":"Tilman","family":"Schneider-Hohendorf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3343-6874","authenticated-orcid":false,"given":"Henrike","family":"Plate","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0174-5042","authenticated-orcid":false,"given":"Tanja","family":"Kuhlmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Schwaninger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6881-4479","authenticated-orcid":false,"given":"Wolfgang","family":"Br\u00fcck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3080-2277","authenticated-orcid":false,"given":"Marc","family":"Pawlitzki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6113-6938","authenticated-orcid":false,"given":"David-Axel","family":"Laplaud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Delphine","family":"Loussouarn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Parratt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Barnett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4755-6471","authenticated-orcid":false,"given":"Michael E.","family":"Buckland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Todd A.","family":"Hardy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen W.","family":"Reddel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3618-8407","authenticated-orcid":false,"given":"Marius","family":"Ringelstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"D\u00f6rr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brigitte","family":"Wildemann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5667-3621","authenticated-orcid":false,"given":"Markus","family":"Kraemer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8617-5052","authenticated-orcid":false,"given":"Hans","family":"Lassmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Romana","family":"H\u00f6ftberger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7266-4098","authenticated-orcid":false,"given":"Eduardo","family":"Beltr\u00e1n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0342-5373","authenticated-orcid":false,"given":"Klaus","family":"Dornmair","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5494-9885","authenticated-orcid":false,"given":"Nicholas","family":"Schwab","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5439-9633","authenticated-orcid":false,"given":"Luisa","family":"Klotz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2571-3501","authenticated-orcid":false,"given":"Sven G.","family":"Meuth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillaume","family":"Martin-Blondel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heinz","family":"Wiendl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5477-5475","authenticated-orcid":false,"given":"Roland","family":"Liblau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,12,18]]},"reference":[{"key":"13593_CR1","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1038\/ni.3666","volume":"18","author":"B Engelhardt","year":"2017","unstructured":"Engelhardt, B., Vajkoczy, P. & Weller, R. O. The movers and shapers in immune privilege of the CNS. Nat. Immunol. 18, 123\u2013131 (2017).","journal-title":"Nat. Immunol."},{"key":"13593_CR2","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/B978-0-444-63432-0.00003-7","volume":"133","author":"B Obermeier","year":"2016","unstructured":"Obermeier, B., Verma, A. & Ransohoff, R. M. The blood-brain barrier. Handb. Clin. Neurol. 133, 39\u201359 (2016).","journal-title":"Handb. Clin. Neurol."},{"key":"13593_CR3","doi-asserted-by":"publisher","first-page":"1064","DOI":"10.1016\/j.cell.2015.10.067","volume":"163","author":"Z Zhao","year":"2015","unstructured":"Zhao, Z., Nelson, A. R., Betsholtz, C. & Zlokovic, B. V. Establishment and dysfunction of the blood-brain barrier. Cell 163, 1064\u20131078 (2015).","journal-title":"Cell"},{"key":"13593_CR4","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1038\/s41593-018-0100-x","volume":"21","author":"B Ajami","year":"2018","unstructured":"Ajami, B. et al. Single-cell mass cytometry reveals distinct populations of brain myeloid cells in mouse neuroinflammation and neurodegeneration models. Nat. Neurosci. 21, 541\u2013551 (2018).","journal-title":"Nat. Neurosci."},{"key":"13593_CR5","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.nbd.2014.09.016","volume":"74","author":"JI Alvarez","year":"2015","unstructured":"Alvarez, J. I. et al. Focal disturbances in the blood-brain barrier are associated with formation of neuroinflammatory lesions. Neurobiol. Dis. 74, 14\u201324 (2015).","journal-title":"Neurobiol. Dis."},{"issue":"12","key":"13593_CR6","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1136\/jnnp-2016-314295","volume":"87","author":"Ilka Kleffner","year":"2016","unstructured":"Kleffner, I. et al. Diagnostic criteria for Susac syndrome. J. Neurol. Neurosurg. Psychiatry 87, 1287\u20131295 (2016).","journal-title":"Journal of Neurology, Neurosurgery & Psychiatry"},{"key":"13593_CR7","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1038\/nrneurol.2013.82","volume":"9","author":"J Dorr","year":"2013","unstructured":"Dorr, J. et al. Characteristics of Susac syndrome: a review of all reported cases. Nat. Rev. Neurol. 9, 307\u2013316 (2013).","journal-title":"Nat. Rev. Neurol."},{"key":"13593_CR8","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1212\/WNL.29.3.313","volume":"29","author":"JO Susac","year":"1979","unstructured":"Susac, J. O., Hardman, J. M. & Selhorst, J. B. Microangiopathy of the brain and retina. Neurology 29, 313\u2013316 (1979).","journal-title":"Neurology"},{"key":"13593_CR9","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1136\/jnnp-2014-308240","volume":"86","author":"TA Hardy","year":"2015","unstructured":"Hardy, T. A. et al. Brain histopathology in three cases of Susac\u2019s syndrome: implications for lesion pathogenesis and treatment. J. Neurol. Neurosurg. Psychiatry 86, 582\u2013584 (2015).","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"13593_CR10","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1309\/AJCPERI7LC4VNFYK","volume":"136","author":"CM Magro","year":"2011","unstructured":"Magro, C. M., Poe, J. C., Lubow, M. & Susac, J. O. Susac syndrome: an organ-specific autoimmune endotheliopathy syndrome associated with anti-endothelial cell antibodies. Am. J. Clin. Pathol. 136, 903\u2013912 (2011).","journal-title":"Am. J. Clin. Pathol."},{"key":"13593_CR11","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1016\/j.jns.2007.01.036","volume":"257","author":"JO Susac","year":"2007","unstructured":"Susac, J. O., Egan, R. A., Rennebohm, R. M. & Lubow, M. Susac\u2019s syndrome: 1975-2005 microangiopathy\/autoimmune endotheliopathy. J. Neurol. Sci. 257, 270\u2013272 (2007).","journal-title":"J. Neurol. Sci."},{"key":"13593_CR12","doi-asserted-by":"publisher","DOI":"10.1186\/1742-2094-11-46","volume":"11","author":"S Jarius","year":"2014","unstructured":"Jarius, S. et al. Clinical, paraclinical and serological findings in Susac syndrome: an international multicenter study. J. Neuroinflammation 11, 46 (2014).","journal-title":"J. Neuroinflammation"},{"key":"13593_CR13","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1159\/000354181","volume":"71","author":"I Kleffner","year":"2013","unstructured":"Kleffner, I. et al. Susac syndrome treated with subcutaneous immunoglobulin. Eur. Neurol. 71, 89\u201392 (2013).","journal-title":"Eur. Neurol."},{"key":"13593_CR14","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1136\/jnnp.2006.095596","volume":"77","author":"I Kleffner","year":"2006","unstructured":"Kleffner, I., Ringelstein, E. B., Stupp, N., Niederstadt, T. U. & Young, P. Neurological picture. Susac\u2019s syndrome: effective combination of immunosuppression and antiplatelet treatment. J. Neurol. Neurosurg. Psychiatry 77, 1335 (2006).","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"13593_CR15","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1007\/s11940-008-0008-y","volume":"10","author":"RM Rennebohm","year":"2008","unstructured":"Rennebohm, R. M., Egan, R. A. & Susac, J. O. Treatment of Susac\u2019s syndrome. Curr. Treat. Options Neurol. 10, 67\u201374 (2008).","journal-title":"Curr. Treat. Options Neurol."},{"key":"13593_CR16","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1093\/jnen\/nlz031","volume":"78","author":"DP Agamanolis","year":"2019","unstructured":"Agamanolis, D. P., Klonk, C., Bigley, K. & Rennebohm, R. M. Neuropathological findings in Susac syndrome: an autopsy report. J. Neuropathol. Exp. Neurol. 78, 515\u2013519 (2019).","journal-title":"J. Neuropathol. Exp. Neurol."},{"key":"13593_CR17","doi-asserted-by":"publisher","first-page":"938","DOI":"10.1056\/NEJM200009283431307","volume":"343","author":"JH Noseworthy","year":"2000","unstructured":"Noseworthy, J. H., Lucchinetti, C., Rodriguez, M. & Weinshenker, B. G. Multiple sclerosis. N. Engl. J. Med. 343, 938\u2013952 (2000).","journal-title":"N. Engl. J. Med."},{"key":"13593_CR18","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1056\/NEJMra1401483","volume":"378","author":"DS Reich","year":"2018","unstructured":"Reich, D. S., Lucchinetti, C. F. & Calabresi, P. A. Multiple sclerosis. N. Engl. J. Med. 378, 169\u2013180 (2018).","journal-title":"N. Engl. J. Med."},{"key":"13593_CR19","doi-asserted-by":"publisher","first-page":"1833","DOI":"10.1084\/jem.20140540","volume":"211","author":"T Schneider-Hohendorf","year":"2014","unstructured":"Schneider-Hohendorf, T. et al. VLA-4 blockade promotes differential routes into human CNS involving PSGL-1 rolling of T cells and MCAM-adhesion of TH17 cells. J. Exp. Med. 211, 1833\u20131846 (2014).","journal-title":"J. Exp. Med."},{"key":"13593_CR20","doi-asserted-by":"publisher","first-page":"2797","DOI":"10.1002\/eji.201343751","volume":"43","author":"YD Mahnke","year":"2013","unstructured":"Mahnke, Y. D., Brodie, T. M., Sallusto, F., Roederer, M. & Lugli, E. The who\u2019s who of T-cell differentiation: human memory T-cell subsets. Eur. J. Immunol. 43, 2797\u20132809 (2013).","journal-title":"Eur. J. Immunol."},{"key":"13593_CR21","doi-asserted-by":"publisher","first-page":"4319","DOI":"10.1073\/pnas.90.9.4319","volume":"90","author":"C Pannetier","year":"1993","unstructured":"Pannetier, C. et al. The sizes of the CDR3 hypervariable regions of the murine T-cell receptor beta chains vary as a function of the recombined germ-line segments. Proc. Natl Acad. Sci. USA 90, 4319\u20134323 (1993).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"13593_CR22","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.jim.2011.09.001","volume":"375","author":"H Robins","year":"2012","unstructured":"Robins, H. et al. Ultra-sensitive detection of rare T cell clones. J. Immunol. Methods 375, 14\u201319 (2012).","journal-title":"J. Immunol. Methods"},{"key":"13593_CR23","doi-asserted-by":"publisher","first-page":"4099","DOI":"10.1182\/blood-2009-04-217604","volume":"114","author":"HS Robins","year":"2009","unstructured":"Robins, H. S. et al. Comprehensive assessment of T-cell receptor beta-chain diversity in alphabeta T cells. Blood 114, 4099\u20134107 (2009).","journal-title":"Blood"},{"key":"13593_CR24","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms11153","volume":"7","author":"T Schneider-Hohendorf","year":"2016","unstructured":"Schneider-Hohendorf, T. et al. CD8(+) T-cell pathogenicity in Rasmussen encephalitis elucidated by large-scale T-cell receptor sequencing. Nat. Commun. 7, 11153 (2016).","journal-title":"Nat. Commun."},{"key":"13593_CR25","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1038\/cr.2012.1","volume":"22","author":"H Li","year":"2012","unstructured":"Li, H., Ye, C., Ji, G. & Han, J. Determinants of public T cell responses. Cell Res. 22, 33\u201342 (2012).","journal-title":"Cell Res."},{"key":"13593_CR26","doi-asserted-by":"publisher","first-page":"3063","DOI":"10.4049\/jimmunol.0903622","volume":"184","author":"L Dong","year":"2010","unstructured":"Dong, L., Li, P., Oenema, T., McClurkan, C. L. & Koelle, D. M. Public TCR use by herpes simplex virus-2-specific human CD8 CTLs. J. Immunol. 184, 3063\u20133071 (2010).","journal-title":"J. Immunol."},{"key":"13593_CR27","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1038\/ng.3822","volume":"49","author":"RO Emerson","year":"2017","unstructured":"Emerson, R. O. et al. Immunosequencing identifies signatures of cytomegalovirus exposure history and HLA-mediated effects on the T cell repertoire. Nat. Genet. 49, 659\u2013665 (2017).","journal-title":"Nat. Genet."},{"key":"13593_CR28","doi-asserted-by":"publisher","first-page":"3439","DOI":"10.1002\/eji.201444662","volume":"44","author":"A Lossius","year":"2014","unstructured":"Lossius, A. et al. High-throughput sequencing of TCR repertoires in multiple sclerosis reveals intrathecal enrichment of EBV-reactive CD8+ T cells. Eur. J. Immunol. 44, 3439\u20133452 (2014).","journal-title":"Eur. J. Immunol."},{"key":"13593_CR29","doi-asserted-by":"publisher","first-page":"7853","DOI":"10.4049\/jimmunol.181.11.7853","volume":"181","author":"V Venturi","year":"2008","unstructured":"Venturi, V. et al. TCR beta-chain sharing in human CD8+ T cell responses to cytomegalovirus and EBV. J. Immunol. 181, 7853\u20137862 (2008).","journal-title":"J. Immunol."},{"key":"13593_CR30","doi-asserted-by":"publisher","first-page":"1603","DOI":"10.1101\/gr.170753.113","volume":"24","author":"A Madi","year":"2014","unstructured":"Madi, A. et al. T-cell receptor repertoires share a restricted set of public and abundant CDR3 sequences that are associated with self-related immunity. Genome Res. 24, 1603\u20131612 (2014).","journal-title":"Genome Res."},{"key":"13593_CR31","doi-asserted-by":"publisher","first-page":"2639","DOI":"10.4049\/jimmunol.1700938","volume":"199","author":"M Di Marco","year":"2017","unstructured":"Di Marco, M. et al. Unveiling the peptide motifs of HLA-C and HLA-G from naturally presented peptides and generation of binding prediction matrices. J. Immunol. 199, 2639\u20132651 (2017).","journal-title":"J. Immunol."},{"key":"13593_CR32","doi-asserted-by":"publisher","first-page":"4790","DOI":"10.4049\/jimmunol.1401689","volume":"193","author":"M Rasmussen","year":"2014","unstructured":"Rasmussen, M. et al. Uncovering the peptide-binding specificities of HLA-C: a general strategy to determine the specificity of any MHC class I molecule. J. Immunol. 193, 4790\u20134802 (2014).","journal-title":"J. Immunol."},{"key":"13593_CR33","doi-asserted-by":"publisher","first-page":"E2973","DOI":"10.1073\/pnas.1524924113","volume":"113","author":"CC Gross","year":"2016","unstructured":"Gross, C. C. et al. Impaired NK-mediated regulation of T-cell activity in multiple sclerosis is reconstituted by IL-2 receptor modulation. Proc. Natl Acad. Sci. USA 113, E2973\u2013E2982 (2016).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"13593_CR34","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1084\/jem.20031579","volume":"199","author":"V Viglietta","year":"2004","unstructured":"Viglietta, V., Baecher-Allan, C., Weiner, H. L. & Hafler, D. A. Loss of functional suppression by CD4+CD25+ regulatory T cells in patients with multiple sclerosis. J. Exp. Med. 199, 971\u2013979 (2004).","journal-title":"J. Exp. Med."},{"key":"13593_CR35","doi-asserted-by":"publisher","first-page":"170ra115","DOI":"10.1126\/scitranslmed.3004970","volume":"5","author":"A Schneider","year":"2013","unstructured":"Schneider, A. et al. In active relapsing-remitting multiple sclerosis, effector T cell resistance to adaptive T(regs) involves IL-6-mediated signaling. Sci. Transl. Med. 5, 170ra115 (2013).","journal-title":"Sci. Transl. Med."},{"key":"13593_CR36","doi-asserted-by":"publisher","first-page":"e77634","DOI":"10.1371\/journal.pone.0077634","volume":"8","author":"B Trinschek","year":"2013","unstructured":"Trinschek, B. et al. Kinetics of IL-6 production defines T effector cell responsiveness to regulatory T cells in multiple sclerosis. PLoS ONE 8, e77634 (2013).","journal-title":"PLoS ONE"},{"key":"13593_CR37","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1007\/s00401-016-1642-1","volume":"133","author":"S Laukoter","year":"2017","unstructured":"Laukoter, S. et al. Differences in T cell cytotoxicity and cell death mechanisms between progressive multifocal leukoencephalopathy, herpes simplex virus encephalitis and cytomegalovirus encephalitis. Acta Neuropathol. 133, 613\u2013627 (2017).","journal-title":"Acta Neuropathol."},{"key":"13593_CR38","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1186\/2045-8118-10-29","volume":"10","author":"S Akanuma","year":"2013","unstructured":"Akanuma, S., Hirose, S., Tachikawa, M. & Hosoya, K. Localization of organic anion transporting polypeptide (Oatp) 1a4 and Oatp1c1 at the rat blood-retinal barrier. Fluids Barriers CNS 10, 29 (2013).","journal-title":"Fluids Barriers CNS"},{"key":"13593_CR39","doi-asserted-by":"publisher","first-page":"2615","DOI":"10.1084\/jem.20110398","volume":"208","author":"DA Ridder","year":"2011","unstructured":"Ridder, D. A. et al. TAK1 in brain endothelial cells mediates fever and lethargy. J. Exp. Med. 208, 2615\u20132623 (2011).","journal-title":"J. Exp. Med."},{"key":"13593_CR40","doi-asserted-by":"publisher","first-page":"988","DOI":"10.1038\/s41591-019-0440-4","volume":"25","author":"H Yousef","year":"2019","unstructured":"Yousef, H. et al. Aged blood impairs hippocampal neural precursor activity and activates microglia via brain endothelial cell VCAM1. Nat. Med. 25, 988\u20131000 (2019).","journal-title":"Nat. Med."},{"key":"13593_CR41","doi-asserted-by":"publisher","first-page":"6366","DOI":"10.1523\/JNEUROSCI.5126-14.2015","volume":"35","author":"DI Scheffer","year":"2015","unstructured":"Scheffer, D. I., Shen, J., Corey, D. P. & Chen, Z. Y. Gene expression by mouse inner ear hair cells during development. J. Neurosci. 35, 6366\u20136380 (2015).","journal-title":"J. Neurosci."},{"key":"13593_CR42","doi-asserted-by":"publisher","first-page":"5053","DOI":"10.1210\/en.2011-1372","volume":"152","author":"DS Sharlin","year":"2011","unstructured":"Sharlin, D. S., Visser, T. J. & Forrest, D. Developmental and cell-specific expression of thyroid hormone transporters in the mouse cochlea. Endocrinology 152, 5053\u20135064 (2011).","journal-title":"Endocrinology"},{"key":"13593_CR43","doi-asserted-by":"publisher","first-page":"359","DOI":"10.4049\/jimmunol.0803388","volume":"183","author":"YM Hyun","year":"2009","unstructured":"Hyun, Y. M., Chung, H. L., McGrath, J. L., Waugh, R. E. & Kim, M. Activated integrin VLA-4 localizes to the lamellipodia and mediates T cell migration on VCAM-1. J. Immunol. 183, 359\u2013369 (2009).","journal-title":"J. Immunol."},{"key":"13593_CR44","doi-asserted-by":"publisher","first-page":"3302","DOI":"10.1002\/eji.201545632","volume":"45","author":"G Martin-Blondel","year":"2015","unstructured":"Martin-Blondel, G. et al. Migration of encephalitogenic CD8 T cells into the central nervous system is dependent on the alpha4beta1-integrin. Eur. J. Immunol. 45, 3302\u20133312 (2015).","journal-title":"Eur. J. Immunol."},{"key":"13593_CR45","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1038\/356063a0","volume":"356","author":"TA Yednock","year":"1992","unstructured":"Yednock, T. A. et al. Prevention of experimental autoimmune encephalomyelitis by antibodies against alpha 4 beta 1 integrin. Nature 356, 63\u201366 (1992).","journal-title":"Nature"},{"key":"13593_CR46","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1056\/NEJMoa044397","volume":"354","author":"CH Polman","year":"2006","unstructured":"Polman, C. H. et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N. Engl. J. Med. 354, 899\u2013910 (2006).","journal-title":"N. Engl. J. Med."},{"key":"13593_CR47","doi-asserted-by":"publisher","first-page":"1270","DOI":"10.1212\/01.WNL.0000159399.81861.D5","volume":"64","author":"BA Cree","year":"2005","unstructured":"Cree, B. A. et al. An open label study of the effects of rituximab in neuromyelitis optica. Neurology 64, 1270\u20131272 (2005).","journal-title":"Neurology"},{"key":"13593_CR48","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.jns.2010.08.028","volume":"299","author":"I Kleffner","year":"2010","unstructured":"Kleffner, I. et al. Neuroimaging in Susac\u2019s syndrome: focus on DTI. J. Neurol. Sci. 299, 92\u201396 (2010).","journal-title":"J. Neurol. Sci."},{"key":"13593_CR49","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1126\/scitranslmed.aao0935","volume":"11","author":"S Nyberg","year":"2019","unstructured":"Nyberg, S., Abbott, N. J., Shi, X., Steyger, P. S. & Dabdoub, A. Delivery of therapeutics to the inner ear: The challenge of the blood-labyrinth barrier. Sci. Transl. Med. 11, 482 (2019).","journal-title":"Sci. Transl. Med."},{"key":"13593_CR50","doi-asserted-by":"publisher","first-page":"E6182","DOI":"10.1073\/pnas.1601350113","volume":"113","author":"L Klotz","year":"2016","unstructured":"Klotz, L. et al. B7-H1 shapes T-cell-mediated brain endothelial cell dysfunction and regional encephalitogenicity in spontaneous CNS autoimmunity. Proc. Natl Acad. Sci. USA 113, E6182\u2013E6191 (2016).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"13593_CR51","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1002\/emmm.201202273","volume":"5","author":"SW Howland","year":"2013","unstructured":"Howland, S. W. et al. Brain microvessel cross-presentation is a hallmark of experimental cerebral malaria. EMBO Mol. Med. 5, 916\u2013931 (2013).","journal-title":"EMBO Mol. Med."},{"key":"13593_CR52","doi-asserted-by":"publisher","first-page":"e1006022","DOI":"10.1371\/journal.ppat.1006022","volume":"12","author":"PA Swanson 2nd","year":"2016","unstructured":"Swanson, P. A. 2nd et al. CD8+ T cells induce fatal brainstem pathology during cerebral malaria via luminal antigen-specific engagement of brain vasculature. PLoS Pathog. 12, e1006022 (2016).","journal-title":"PLoS Pathog."},{"key":"13593_CR53","doi-asserted-by":"publisher","first-page":"16001","DOI":"10.1038\/nmicrobiol.2016.1","volume":"1","author":"C Konradt","year":"2016","unstructured":"Konradt, C. et al. Endothelial cells are a replicative niche for entry of Toxoplasma gondii to the central nervous system. Nat. Microbiol. 1, 16001\u201316001 (2016).","journal-title":"Nat. Microbiol."},{"key":"13593_CR54","doi-asserted-by":"publisher","first-page":"11270","DOI":"10.1073\/pnas.0800898105","volume":"105","author":"EE McCandless","year":"2008","unstructured":"McCandless, E. E., Zhang, B., Diamond, M. S. & Klein, R. S. CXCR4 antagonism increases T cell trafficking in the central nervous system and improves survival from West Nile virus encephalitis. Proc. Natl Acad. Sci. 105, 11270\u201311275 (2008).","journal-title":"Proc. Natl Acad. Sci."},{"key":"13593_CR55","doi-asserted-by":"publisher","first-page":"2000","DOI":"10.1172\/JCI97098","volume":"128","author":"H Kebir","year":"2018","unstructured":"Kebir, H. et al. Humanized mouse model of Rasmussen\u2019s encephalitis supports the immune-mediated hypothesis. J. Clin. Invest. 128, 2000\u20132009 (2018).","journal-title":"J. Clin. Invest."},{"key":"13593_CR56","doi-asserted-by":"crossref","unstructured":"Breuer, J. et al. Dual action by fumaric acid esters synergistically reduces adhesion to human endothelium. Mult. Scler. 1352458517735189 (2017).","DOI":"10.1177\/1352458517735189"},{"key":"13593_CR57","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1089\/104454901753438561","volume":"20","author":"P Champagne","year":"2001","unstructured":"Champagne, P., Dumont, A. R. & Sekaly, R. P. Learning to remember: generation and maintenance of T-cell memory. DNA Cell Biol. 20, 745\u2013760 (2001).","journal-title":"DNA Cell Biol."},{"key":"13593_CR58","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1084\/jem.186.9.1407","volume":"186","author":"D Hamann","year":"1997","unstructured":"Hamann, D. et al. Phenotypic and functional separation of memory and effector human CD8+ T cells. J. Exp. Med. 186, 1407\u20131418 (1997).","journal-title":"J. Exp. Med."},{"key":"13593_CR59","doi-asserted-by":"publisher","first-page":"4905","DOI":"10.4049\/jimmunol.1501029","volume":"196","author":"Y Zhao","year":"2016","unstructured":"Zhao, Y. et al. Preferential use of public TCR during autoimmune encephalomyelitis. J. Immunol. 196, 4905\u20134914 (2016).","journal-title":"J. Immunol."},{"key":"13593_CR60","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1038\/44385","volume":"401","author":"F Sallusto","year":"1999","unstructured":"Sallusto, F., Lenig, D., Forster, R., Lipp, M. & Lanzavecchia, A. Two subsets of memory T lymphocytes with distinct homing potentials and effector functions. Nature 401, 708\u2013712 (1999).","journal-title":"Nature"},{"key":"13593_CR61","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1038\/nri3279","volume":"12","author":"AK Sewell","year":"2012","unstructured":"Sewell, A. K. Why must T cells be cross-reactive? Nat. Rev. Immunol. 12, 669 (2012).","journal-title":"Nat. Rev. Immunol."},{"key":"13593_CR62","doi-asserted-by":"publisher","first-page":"2485","DOI":"10.1084\/jem.20121015","volume":"209","author":"H Frebel","year":"2012","unstructured":"Frebel, H. et al. Programmed death 1 protects from fatal circulatory failure during systemic virus infection of mice. J. Exp. Med. 209, 2485\u20132499 (2012).","journal-title":"J. Exp. Med."},{"key":"13593_CR63","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1038\/nm0402-379","volume":"8","author":"V Appay","year":"2002","unstructured":"Appay, V. et al. Memory CD8+ T cells vary in differentiation phenotype in different persistent virus infections. Nat. Med. 8, 379\u2013385 (2002).","journal-title":"Nat. Med."},{"key":"13593_CR64","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1038\/35065118","volume":"410","author":"P Champagne","year":"2001","unstructured":"Champagne, P. et al. Skewed maturation of memory HIV-specific CD8 T lymphocytes. Nature 410, 106\u2013111 (2001).","journal-title":"Nature"},{"key":"13593_CR65","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1016\/j.jns.2009.07.002","volume":"285","author":"S Jarius","year":"2009","unstructured":"Jarius, S., Neumayer, B., Wandinger, K. P., Hartmann, M. & Wildemann, B. Anti-endothelial serum antibodies in a patient with Susac\u2019s syndrome. J. Neurol. Sci. 285, 259\u2013261 (2009).","journal-title":"J. Neurol. Sci."},{"issue":"6 Suppl","key":"13593_CR66","first-page":"S164","volume":"16","author":"PK Coyle","year":"2010","unstructured":"Coyle, P. K. The role of natalizumab in the treatment of multiple sclerosis. Am. J. Manag. Care 16(6 Suppl), S164\u2013S170 (2010).","journal-title":"Am. J. Manag. Care"},{"key":"13593_CR67","doi-asserted-by":"publisher","first-page":"e151","DOI":"10.1212\/NXI.0000000000000151","volume":"2","author":"L Zhovtis Ryerson","year":"2015","unstructured":"Zhovtis Ryerson, L., Kister, I., Snuderl, M., Magro, C. & Bielekova, B. Incomplete Susac syndrome exacerbated after natalizumab. Neurol. Neuroimmunol. Neuroinflamm. 2, e151 (2015).","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"13593_CR68","doi-asserted-by":"crossref","unstructured":"Rennebohm, R. M., Asdaghi, N., Srivastava, S. & Gertner, E. Guidelines for treatment of Susac syndrome - an update. Int. J. Stroke 1747493017751737 (2018).","DOI":"10.1177\/1747493017751737"},{"key":"13593_CR69","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1212\/WNL.0b013e31829c5ceb","volume":"81","author":"S Bittner","year":"2013","unstructured":"Bittner, S. et al. Rasmussen encephalitis treated with natalizumab. Neurology 81, 395\u2013397 (2013).","journal-title":"Neurology"},{"key":"13593_CR70","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1002\/ana.22366","volume":"69","author":"CH Polman","year":"2011","unstructured":"Polman, C. H. et al. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann. Neurol. 69, 292\u2013302 (2011).","journal-title":"Ann. Neurol."},{"key":"13593_CR71","doi-asserted-by":"publisher","first-page":"1194","DOI":"10.1111\/j.1365-2826.2011.02216.x","volume":"23","author":"MF Lang","year":"2011","unstructured":"Saxena, A. I. et al.\u00a0Cutting edge: Multiple sclerosis-like lesions induced by effector CD8 T cells recognizing a sequestered antigen on oligodendrocytes.\u00a0J. Immunol.\u00a0181, 1617\u20131621 (2008).","journal-title":"J. Neuroendocrinol."},{"key":"13593_CR72","doi-asserted-by":"crossref","first-page":"978","DOI":"10.4049\/jimmunol.157.3.978","volume":"157","author":"DJ Morgan","year":"1996","unstructured":"Morgan, D. J. et al. CD8(+) T cell-mediated spontaneous diabetes in neonatal mice. J. Immunol. 157, 978\u2013983 (1996).","journal-title":"J. Immunol."},{"issue":"Pt 11","key":"13593_CR73","doi-asserted-by":"publisher","first-page":"2789","DOI":"10.1093\/brain\/awm214","volume":"130","author":"A Junker","year":"2007","unstructured":"Junker, A. et al. Multiple sclerosis: T-cell receptor expression in distinct brain regions. Brain 130(Pt 11), 2789\u20132799 (2007).","journal-title":"Brain"},{"key":"13593_CR74","doi-asserted-by":"publisher","first-page":"127","DOI":"10.3109\/08916939608995336","volume":"23","author":"J Monteiro","year":"1996","unstructured":"Monteiro, J., Hingorani, R., Peroglizzi, R., Apatoff, B. & Gregersen, P. K. Oligoclonality of CD8+ T cells in multiple sclerosis. Autoimmunity 23, 127\u2013138 (1996).","journal-title":"Autoimmunity"},{"key":"13593_CR75","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1182\/blood-2012-07-442558","volume":"121","author":"SC Chiang","year":"2013","unstructured":"Chiang, S. C. et al. Comparison of primary human cytotoxic T-cell and natural killer cell responses reveal similar molecular requirements for lytic granule exocytosis but differences in cytokine production. Blood 121, 1345\u20131356 (2013).","journal-title":"Blood"}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-019-13593-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-019-13593-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-019-13593-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,24]],"date-time":"2023-09-24T00:53:52Z","timestamp":1695516832000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-019-13593-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12,18]]},"references-count":75,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2019,12]]}},"alternative-id":["13593"],"URL":"https:\/\/doi.org\/10.1038\/s41467-019-13593-5","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,12,18]]},"assertion":[{"value":"3 September 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 November 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 December 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"C.C.G. received speaker honoraria and travel expenses for attending meetings from Biogen, Euroimmun, Genzyme, MyLan, Novartis Pharma GmbH, and Bayer Health Care, none related to this study. Her work is funded by Biogen, Novartis, the German Ministry for Education and Research (BMBF; 01Gl1603A), the German Research Foundation (DFG, GR3946\/3\u20131, SFB Transregio 128 A09), the European Union (Horizon2020, ReSToRE), the Interdisciplinary Center for Clinical Studies (IZKF), and the IMF. I.K. received travel expenses for attending meetings from Pfizer and CSL Behring. I.K. received speaker honoraria from Daiichi Sankyo. J.B.\u2019s work is funded by the Austrian Science Fund (FWF: P26936-B27). A.S.-M. receives research support from Novartis. T.K. received speaker honoraria from Novartis and Excemed. Her research is supported by the DFG (SFB\/Transregio 128 B07), European Leukodystrophy Association (2017-018C4A), National MS Society (RG-1801-30020), and Progressive MS Alliance (PA-1604-08492, VRAVEinMS). W.B. has received honoraria for lectures by Bayer Vital, Biogen, Merck Serono, Teva Pharma, Genzyme, Sanofi-Aventis, Novartis, Excemed, and Medday. He is a member of scientific advisory boards for Teva Pharma, Biogen, Novartis, and Genzyme. W.B. receives research support from Teva Pharma, Biogen, Genzyme, and Novartis. W.B. is supported by the Deutsche Forschungsgemeinschaft, the German Ministry for Education and Research, and by the Klaus Tschira Foundation. M.P. received speaker honoraria from Roche and Genzyme and travel\/accommodation\/meeting expenses from Novartis, Biogen Idec, Genzyme, and MERCK Serono. D.-A.L. received speaker honoraria from Biogen, Merck, Novartis, Roche, Teva, and Genzyme and non-personal grants from Biogen, Genzyme, Novartis, MedDay, Merck, and Roche not related to this study. J.P. is a member of scientific advisory boards from Genzyme and Novartis. He received honoraria from Biogen, Sanofi\/Genzyme, and Merck Serono. M.B. received institutional support for research, speaking and\/or participation in advisory boards for Biogen, Merck, Novartis, Roche, and Sanofi Genzyme. He is a consulting neurologist for RxMx\/Medical Safety Systems and a research director for Sydney Neuroimaging Analysis Centre. T.A.H. has received honoraria or travel sponsorship from Bayer-Schering, Novartis, Biogen Idec, Merck-Serono, Roche, Teva, Alexion, and Sanofi-Genzyme. S.W.R. has received honoraria, travel sponsorship, research, and\/or departmental support from MGANSW, MGAQLD, MAA, Lambert Initiative, Beeren foundation, anonymous donors, and from pharmaceutical\/biological companies: Baxter, Bayer Schering, Biogen Idec, CSL, Genzyme, Grifols, Octapharma, Merck, Novartis, Roche, Sanofi Aventis Genzyme, Servier, and TEVA. Relevant to this study, Biogen is the manufacturer of natalizumab. S.W.R. is a shareholder of Medical Safety Systems trading as RxMx (grant and contracts with Genzyme >$25,000 AUD, contracts with Novartis, Roche, Janssen). M.R. received speaker honoraria from Novartis, Bayer Vital GmbH, and Ipsen and travel reimbursement from Bayer Schering, Biogen Idec, Merz, Genzyme, Teva, and Merck, none related to this study. J.D. received research support by Bayer and Novartis, travel support by Bayer, Novartis, Biogen, and Merck Serono, and honoraria for lectures and advisory by Bayer, Novartis, Biogen, Merck Serono, Roche, and Sanofi Genzyme. B.W. received research support from German Ministry of Education and Research, Dietmar Hopp Foundation, Klaus Tschira Foundation, Sanofi Genzyme, Merck Serono, and Novartis and speaker honoraria and\/or travel support from Bayer Healthcare, Biogen, Merck Serono, Novartis, Sanofi Genzyme, and TEVA outside the submitted work. M.K. received travel support and honoraria from Bayer Schering, Biogen Idec, Chugai Pharma, Merck Serono, Novartis Pharma, Teva Pharma, and Shire Deutschland. H.L. received honoraria for lectures and consultation related to multiple sclerosis from Novartis, Roche, Sanofi Aventis, Biogen, and MEDDAY. R.H. received speaker honoraria from Euroimmun and research support from the Jubil\u00e4umsfonds der \u00d6stereichischen Nationalbank (project 16919) and the Austrian Science Fund (FWF: I3334-B27). N.S. received travel support from Novartis and Sanofi-Genzyme. L.K. received compensation for serving on scientific advisory boards for Genzyme, Merck, Novartis, and Roche; speaker honoraria and travel support from Biogen, Genzyme, Merck, Novartis, and Roche; and research support from Biogen, Genzyme, Merck, Novartis, and Roche, the German Ministry for Education and Research (BMBF), Deutsche Forschungsgesellschaft (DFG), and the Interdisciplinary Center for Clinical Studies (IZKF) M\u00fcnster. S.G.M. receives honoraria for lecturing, and travel expenses for attending meetings from Almirall, Amicus Therapeutics Germany, Bayer Health Care, Biogen, Celgene, Diamed, Genzyme, MedDay Pharmaceuticals, Merck Serono, Novartis, Novo Nordisk, ONO Pharma, Roche, Sanofi-Aventis, Chugai Pharma, QuintilesIMS, and Teva. His research is funded by the German Ministry for Education and Research (BMBF), Deutsche Forschungsgesellschaft (DFG), Else Kr\u00f6ner Fresenius Foundation, German Academic Exchange Service, Hertie Foundation, Interdisciplinary Center for Clinical Studies (IZKF) Muenster, German Foundation Neurology and Almirall, Amicus Therapeutics Germany, Biogen, Diamed, Fresenius Medical Care, Genzyme, Merck Serono, Novartis, ONO Pharma, Roche, and Teva. G.M.-B. received speaker honoraria and travel support for attending meetings from Abbvie, Genzyme, Gilead, and Pfizer. H.W. received honoraria for scientific advisory boards\/steering committees from Biogen, Evgen, MedDay Pharmaceuticals, Merck Serono, Novartis, Roche Pharma AG, and Sanofi-Genzyme. He received speaker honoraria and travel support for attending meetings from Alexion, Biogen, Cognomed, F. Hoffmann-La Roche Ltd., Gemeinn\u00fctzige Hertie-Stiftung, Merck Serono, Novartis, Roche Pharma AG, Sanofi-Genzyme, TEVA, and WebMD Globa. H.W. received compensation as a consultant from Abbvie, Actelion, Biogen, IGES, Novartis, Roche, Sanofi-Genzyme, and the Swiss Multiple Sclerosis Society. He also received research support from the German Ministry for Education and Research (BMBF), Deutsche Forschungsgesellschaft (DFG), Else Kr\u00f6ner Fresenius Foundation, Fresenius Foundation, Hertie Foundation, NRW Ministry of Education and Research, Interdisciplinary Center for Clinical Studies (IZKF) Muenster and RE Children\u2019s Foundation, Biogen GmbH, GlaxoSmithKline GmbH, Roche Pharma AG, and Sanofi-Genzyme. R.L. received grant support from Pierre Fabre, GlaxoSmithKline, and Diaccurate. He received speaker or scientific board honoraria from Biogen, Servier, Novartis, and Sanofi-Genzyme. R.L. is currently receiving grants from GlaxoSmithKline, Cancer Research Institute, French Cancer research foundation (ARC), Rare Diseases Foundation, and National Institute of Cancer (INCa). C.M., U.B., L.Y., A.T., S.H., T.S.-H., H.P., M.S., D.L., M.E.B., E.B., and K.D. have no financial disclosures.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"5779"}}